Last reviewed · How we verify
Liposomal bupivacaine TAP block
Liposomal bupivacaine TAP block is a Small molecule drug developed by University of Virginia. It is currently FDA-approved. Also known as: Exparel TAP block.
At a glance
| Generic name | Liposomal bupivacaine TAP block |
|---|---|
| Also known as | Exparel TAP block |
| Sponsor | University of Virginia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- EOIFP Block Versus OSTAP Block for Upper Abdominal Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (PHASE3)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids (PHASE2, PHASE3)
- Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy (PHASE4)
- Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal bupivacaine TAP block CI brief — competitive landscape report
- Liposomal bupivacaine TAP block updates RSS · CI watch RSS
- University of Virginia portfolio CI
Frequently asked questions about Liposomal bupivacaine TAP block
What is Liposomal bupivacaine TAP block?
Liposomal bupivacaine TAP block is a Small molecule drug developed by University of Virginia.
Who makes Liposomal bupivacaine TAP block?
Liposomal bupivacaine TAP block is developed and marketed by University of Virginia (see full University of Virginia pipeline at /company/university-of-virginia).
Is Liposomal bupivacaine TAP block also known as anything else?
Liposomal bupivacaine TAP block is also known as Exparel TAP block.
What development phase is Liposomal bupivacaine TAP block in?
Liposomal bupivacaine TAP block is FDA-approved (marketed).
Related
- Manufacturer: University of Virginia — full pipeline
- Also known as: Exparel TAP block
- Compare: Liposomal bupivacaine TAP block vs similar drugs
- Pricing: Liposomal bupivacaine TAP block cost, discount & access